Business Wire

HEINEKEN Teams Up With Blue Yonder To Improve Demand Planning

15.5.2024 11:00:00 EEST | Business Wire | Press release

Share

HEINEKEN, the world’s most international brewer, confirms Blue Yonder as a vendor of trust to further transform its supply chain planning capability. The global brewer will implement Blue Yonder Cognitive Demand Planning, a next generation cloud-native, microservices-based SaaS solution, that utilizes artificial intelligence (AI) and machine learning (ML) to improve forecast accuracy and reduce bias by considering dynamic external and internal variables.

HEINEKEN has been implementing Blue Yonder solutions for multiple years unlocking value for its business, especially with the potential to improve forecast accuracy through ML demand forecasting solution. HEINEKEN has selected Blue Yonder, as one of the current major supply chain solution providers, to future proof its demand planning process and leverage AI/ML, autonomous scenario planning, planning process orchestration and solution extensibility.

“We want to continuously improve our supply chain processes and adopting Blue Yonder Cognitive Demand Planning is an important step in that ambition. Working together with Blue Yonder will support us in our ambition to become the best-connected brewer and foster functional excellence in demand planning, leading to improved customer experience. And with the right supply response it could generate a positive impact on our sustainability targets as well, for example by reduced write-offs and less goods movements,” said Corneel Hindriks, manager, Digital & Technology - Global Planning, HEINEKEN.

Once the Blue Yonder Cognitive Demand Planning solution is implemented, HEINEKEN expects to achieve the following benefits:

  • Make more informed, data-driven decisions: get all the real-world and business data HEINEKEN needs in a unified data cloud and integrate all planning processes to make better decisions – with speed and scale.
  • Manage complexity and boost accuracy: combine the best output from statistical forecasting and extensible ML to deliver higher forecast accuracy and reduce bias.
  • Respond faster: compress the planning cycle and empower planners to drive strategy and respond in the moment, not on a fixed schedule.
  • Create and deploy customized and extended solutions: build, test and confidently deploy customized and extended ML models, workflows, personalized user experiences, and business logic at production scale with minimal effort.

Consumer goods companies are currently encountering challenges due to fluctuations in demand caused by inflation, supply chain disruptions, evolving consumer habits, and a growing demand for more sustainable products and processes. These industry dynamics pose a significant challenge for conventional forecasting methods. Blue Yonder Cognitive Demand Planning solution, which sits on Microsoft Azure, addresses these challenges with a new generation of AI-based capabilities, transforming the way companies around the world collaborate, predict, plan and make decisions.

“We are proud to bring our contribution as supply chain management leaders in supporting HEINEKEN’s mission to become the best-connected brewer. Blue Yonder’s future-proof solution helps a brewer like HEINEKEN to adapt to new external dynamics and changing market conditions, ensuring their supply chains remain agile, sustainable and competitive. Thanks to Blue Yonder Cognitive Demand Planning, HEINEKEN can optimize its supply chain and ensure that customers can always enjoy their preferred beers and beyond all over the world,” said Terry Turner, President, Manufacturing, Blue Yonder.

Additional Resources:

About Heineken

HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 350 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 90,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brew a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, maltings, cider plants and other production facilities in more than 70 countries. The most recent information is available on the Company's website and follow us on LinkedIn, Twitter and Instagram. For press inquiry please contact pressoffice@heineken.com.

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential™ blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Blue Yonder Public Relations:
Marina Renneke, APR, Global Corporate Communications Sr. Director
Tel: +1 480-308-3037, marina.renneke@blueyonder.com

Rossella Benti, EMEA Corporate Communications Director
Tel: +39 335 7849149, rossella.benti@blueyonder.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye